DX
Daisy Xu
OtherActiveGeneral Director at Vivo Capital
79
Investments
0
Exits
—
AUM
0.0%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Daisy Xu.
Investment Thesis & Strategy
Daisy Xu, as a General Director at Vivo Capital, invests in various stages of biotech and medical device companies, likely seeking innovative and high-growth opportunities within the healthcare sector.
Portfolio Companies
Selected investments from their portfolio of 79 companies
A
Aclaris Therapeutics
Biotech · Series B, 0
B
Biohaven Pharmaceutical
Biotech · Series B, 0
A
Amyris
Biotech · Series C+, 0
R
Rongchang Pharmaceutical
Biotech · Series C+, 0
R
Remegen
Biotech · Series C+, 0
G
Gengmei
Healthcare · Series B, 0
C
Celladon
Biotech · Series B, 0
R
REGENXBIO
Biotech · Series B, 0
P
PatientPop
SaaS · Series B, 0
P
Passage Bio
Biotech · Series B, 0
P
Preventice Solutions
Other · , 0
P
Poseida Therapeutics
Other · , 0
Frequently Asked Questions
Daisy Xu focuses on Series B stage investments.